Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2021 | Update on pediatric NMOSD and MOGAD

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) are central nervous system (CNS) demyelinating inflammatory disorders, distinct from each other and from multiple sclerosis (MS). Each disorder has a different clinical phenotype, prognosis, and management. Brenda Banwell, MD, FAAN, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the latest clinical understanding of pediatric MOGAD and NMOSD, as well as current treatment approaches. Dr Banwell highlights the need for comparative trials in MOGAD to determine the optimal treatment approach. Several important trials in adults with NMOSD have recently taken place, showing substantial efficacy of therapies targeted against C5b-9, IL-6, and CD20. It is hoped these findings could translate to the pediatric setting. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.


Dr Banwell has served as an advisor for pediatric MS clinical trials for Novartis, Teva Neuroscience, UCB and Roche.